CS237346B2 - Processing of racemic or opticaly active 5-substituted oxazolidine-2,4-dione - Google Patents

Processing of racemic or opticaly active 5-substituted oxazolidine-2,4-dione Download PDF

Info

Publication number
CS237346B2
CS237346B2 CS838032A CS803283A CS237346B2 CS 237346 B2 CS237346 B2 CS 237346B2 CS 838032 A CS838032 A CS 838032A CS 803283 A CS803283 A CS 803283A CS 237346 B2 CS237346 B2 CS 237346B2
Authority
CS
Czechoslovakia
Prior art keywords
alkoxy
thienyl
group
carbon atoms
alkyl
Prior art date
Application number
CS838032A
Other languages
Czech (cs)
English (en)
Other versions
CS803283A2 (en
Inventor
Rodney C Schnur
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/252,962 external-priority patent/US4342771A/en
Application filed by Pfizer filed Critical Pfizer
Priority claimed from CS815646A external-priority patent/CS237320B2/cs
Publication of CS803283A2 publication Critical patent/CS803283A2/cs
Publication of CS237346B2 publication Critical patent/CS237346B2/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/51—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition
    • C07C45/511—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition involving transformation of singly bound oxygen functional groups to >C = O groups
    • C07C45/513—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition involving transformation of singly bound oxygen functional groups to >C = O groups the singly bound functional group being an etherified hydroxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CS838032A 1980-07-28 1981-07-23 Processing of racemic or opticaly active 5-substituted oxazolidine-2,4-dione CS237346B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17320680A 1980-07-28 1980-07-28
US06/252,962 US4342771A (en) 1981-01-02 1981-04-23 Hypoglycemic 5-substituted oxazolidine-2,4-diones
US06/252,961 US4332952A (en) 1980-07-28 1981-04-23 Hypoglycemic 5-substituted oxazolidine-2,4-diones
CS815646A CS237320B2 (en) 1980-07-28 1981-07-23 Processing of racemic or opticaly active 5-substituted oxazolidine-2,4-dione

Publications (2)

Publication Number Publication Date
CS803283A2 CS803283A2 (en) 1984-12-14
CS237346B2 true CS237346B2 (en) 1985-07-16

Family

ID=26868873

Family Applications (2)

Application Number Title Priority Date Filing Date
CS838032A CS237346B2 (en) 1980-07-28 1981-07-23 Processing of racemic or opticaly active 5-substituted oxazolidine-2,4-dione
CS838034A CS237348B2 (en) 1980-07-28 1983-10-31 Processing of racemic or optically active 5-substituted oxazolidine-2,4-dione

Family Applications After (1)

Application Number Title Priority Date Filing Date
CS838034A CS237348B2 (en) 1980-07-28 1983-10-31 Processing of racemic or optically active 5-substituted oxazolidine-2,4-dione

Country Status (3)

Country Link
US (1) US4332952A (de)
AT (3) AT376976B (de)
CS (2) CS237346B2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689336A (en) * 1981-01-02 1987-08-25 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine 2,4-diones
US4423233A (en) * 1981-04-23 1983-12-27 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4430337A (en) 1982-06-23 1984-02-07 Pfizer Inc. Alicyclic substituted oxazolidine-2,4-diones having hypoglycemic activity
CA1334975C (en) * 1987-11-13 1995-03-28 James H. Holms Furan and pyrrole containing lipoxygenase inhibiting compounds
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5498621A (en) * 1992-05-01 1996-03-12 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5401761A (en) * 1993-12-09 1995-03-28 Pfizer, Inc. Thiazolidinedione hypoglycemic agents
TW403748B (en) * 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
US6380191B1 (en) 1999-06-18 2002-04-30 Merck & Co. Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
CA2376919C (en) 1999-06-18 2008-11-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
US6638929B2 (en) * 1999-12-29 2003-10-28 Wyeth Tricyclic protein kinase inhibitors
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
CA2536622C (en) * 2003-08-29 2014-02-11 The Brigham And Women's Hospital, Inc. Inhibitors of cellular necrosis
CA2772760A1 (en) 2008-12-23 2010-07-01 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
US20160024098A1 (en) 2013-03-15 2016-01-28 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
EP3229807A4 (de) 2014-12-11 2018-10-17 President and Fellows of Harvard College Hemmer von zellulärer nekrose und zugehörige verfahren
WO2025196206A1 (en) * 2024-03-20 2025-09-25 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2338220A (en) * 1942-01-31 1944-01-04 Mallinckrodt Chemical Works Process of making oxazolidinediones
US2721197A (en) * 1953-01-05 1955-10-18 Bristol Lab Inc Bicyclic lactams
US3699229A (en) * 1970-12-18 1972-10-17 Abbott Lab 2-oxo-5-phenyl-4-oxazolidinone as an anti-depressant agent
DE2813873A1 (de) * 1978-03-31 1979-10-11 Basf Ag Verfahren zur herstellung von oxazolidin-2,4-dionen

Also Published As

Publication number Publication date
CS237348B2 (en) 1985-07-16
CS803283A2 (en) 1984-12-14
CS803483A2 (en) 1984-12-14
ATA54084A (de) 1984-06-15
AT376977B (de) 1985-01-25
AT376975B (de) 1985-01-25
AT376976B (de) 1985-01-25
US4332952A (en) 1982-06-01
ATA53984A (de) 1984-06-15
ATA53884A (de) 1984-06-15

Similar Documents

Publication Publication Date Title
JP4276074B2 (ja) ペルオキシソーム増殖剤応答性受容体δの活性化剤
CS237346B2 (en) Processing of racemic or opticaly active 5-substituted oxazolidine-2,4-dione
JP3997491B2 (ja) カルバゾール誘導体、その溶媒和物、又は薬学的に許容されるその塩
KR101507173B1 (ko) 페록시좀 증식제 활성화 수용체 δ 의 활성화제
EP2393809B1 (de) Derivate von azaspiranylalkylcarbamaten 5-gliedriger heterocyclischer verbindungen, deren herstellung und deren therapeutische verwendung
JP6118340B2 (ja) １１−β−ヒドロキシステロイドデヒドロゲナーゼ阻害剤としての環状アミド誘導体およびその使用
EA020209B1 (ru) Способ получения соединений, применимых в качестве ингибиторов натрийзависимого переносчика глюкозы
EA028946B1 (ru) Способ получения соединений для применения в качестве ингибиторов sglt2
CZ283680B6 (cs) Nové azaheterocyklylmethyl-chromany
CS244946B2 (en) Production method of racemic or opticaly active 5-substituted oxazoline-2-4-diones
EA018620B1 (ru) ПРОИЗВОДНЫЕ ТИЕНОТРИАЗОЛОДИАЗЕПИНА, АКТИВНЫЕ В ОТНОШЕНИИ Apo A1
RU2296759C2 (ru) N-замещенные 1н-индол-5-пропионовые кислоты, фармацевтическая композиция, содержащая эти соединения, и их применение (варианты)
CS237320B2 (en) Processing of racemic or opticaly active 5-substituted oxazolidine-2,4-dione
JP2002510623A (ja) 抗糖尿病薬
WO2015057629A1 (en) ALKYL LINKED QUINOLINYL MODULATORS OF RORyt
WO2011080445A1 (fr) NOUVEAUX DERIVES (HETEROCYCLE-TETRAHYDRO-PYRIDINE)-(PIPERAZINYL)-1-ALCANONE ET (HETEROCYCLE-DIHYDRO-PYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE ET LEUR UTILISATION COMME INHIBITEURS DE p75
JP2002322163A (ja) ピペラジン誘導体
EP0579169A1 (de) Alkylendiamine Derivate
KR102640385B1 (ko) 고혈압 및/또는 폐 섬유증 치료용 조성물
US4381308A (en) Hypoglycemic 5-substituted oxazolidine-2,4-diones
JP2724396B2 (ja) 骨粗鬆症予防治療剤
CS237347B2 (en) Processing of racemic or optically active 5-substituted oxazolidine-2,4-dione
KR850000384B1 (ko) 5-치환된 옥사졸리딘-2, 4-디온의 제조방법
JP3074332B2 (ja) ホスホン酸ジエステル誘導体
US20080293721A1 (en) Arylthioacetamide carboxylate derivatives as fkbp inhibitors for the treatment of neurological diseases